Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) just unveiled an update.
HighTide Therapeutics, Inc. has announced a new research collaboration with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, to explore the therapeutic potential of its core product, HTD1801, for treating type 2 diabetes mellitus with chronic kidney disease. This partnership aims to accelerate clinical advancements and expand the company’s strategic research and development efforts, enhancing its product pipeline and supporting long-term innovation in metabolic disease treatment.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company that focuses on discovering and developing first-in-class multifunctional, multi-targeted therapies with potential applications across various metabolic diseases. The company is advancing several clinical assets and holds global intellectual property rights, with HTD1801 as its lead drug candidate, which has received Fast Track and Orphan Drug designations from the U.S. FDA.
Average Trading Volume: 2,813,099
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.81B
Find detailed analytics on 2511 stock on TipRanks’ Stock Analysis page.